^
3ms
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=22, Terminated, Coherus Biosciences, Inc. | Trial completion date: Jan 2026 --> Jul 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Jul 2024; The study was terminated for strategic reasons (not for safety concerns)
Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Loqtorzi (toripalimab-tpzi) • JS006
9ms
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=22, Active, not recruiting, Coherus Biosciences, Inc. | Recruiting --> Active, not recruiting | N=100 --> 22
Enrollment closed • Enrollment change • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • MET mutation • ROS1 mutation
|
Loqtorzi (toripalimab-tpzi) • JS006
over1year
Enrollment open • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • MET mutation • ROS1 mutation
|
Loqtorzi (toripalimab-tpzi) • JS006
over1year
New P1/2 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation • MET mutation • ROS1 mutation
|
Loqtorzi (toripalimab-tpzi) • JS006